You are here

Article Text

Article menu

Download PDFPDF

Endometrial cancer
2022-RA-997-ESGO Lung recurrence of endometrial adenocarcinoma: impact of molecular profile and role of local therapies on prognosis
Free
  1. Ana Luzarraga1,
  2. Vicente Bebia1,
  3. Carlos Lopez-Gil2,
  4. Maria Pilar Montoya3,
  5. Alexandra Giraldo4,
  6. Alberto Jauregui3,
  7. Ramona Verges4,
  8. Josep Castellvi5,
  9. Angel Garcia-Jimenez5,
  10. Eva Colas2,
  11. Antonio Gil6 and
  12. Silvia Cabrera6
  1. 1Gynecologic Oncology, Hospital Vall d’Hebron, Barcelona, Spain
  2. 2Vall d’Hebron Research Institute (VHIR), Barcelona, Spain
  3. 3Thoracic surgery, Hospital vall Hebron, Barcelona, Spain
  4. 4Radiation Oncology, Hospital vall Hebron, Barcelona, Spain
  5. 5Anatomy, Hospital vall Hebron, Barcelona, Spain
  6. 6Vall Hebron Hospital, Barcelona, Spain

Abstract

Introduction/Background Endometrial cancer(EC) lung recurrence can be classified as multiple-site recurrence (affecting the lung and other organs) or isolated lung recurrence (affecting only the lung). Isolated lung recurrent patients may have the potential for long-term disease control and improved prognosis with local treatments: stereotactic body radiation therapy (SBRT) or metastasectomy.

Methodology This is a retrospective single-center study including consecutive women diagnosed with stage I-IVA EC at the Hospital Vall d’Hebron between 1995 and 2021 with first recurrence affecting the lung. Patients were classified as multiple-site metastatic or isolated lung recurrence, and these last according to the treatment received (local or systemic). We aimed to analyze local response rate and prognostic outcomes according to received treatment and the molecular classification (MC).

Results Isolated lung systemic-treated patients (n=15) were older (77 vs 69.7 years-old at relapse,p=0.43) and had more often bilateral (73.3%vs37.5%, p=0.008) and a higher number of metastases (p=0,001) than locally-treated patients (n=16). Of the locally-treated group, 5 were treated with SBRT and 11 with surgery. Complete response was achieved in 80% and 90.9%, respectively. 9(56%) vs 1(11,1%) patients were alive and without disease at the end of follow-up (median follow-up: 5.9 years) in local and systemic treatment groups, respectively(p=0,05)(Image2). Median-time-to-progression was higher in local-treatment group (3,5 ys vs 0,7 ys, p=0.029), as well as 5-year-OS (80,8% vs 44,4%, p=0.88). No statistically significant differences were found between multiple-site metastasic patients and isolated lung recurrent patients regarding molecular profiling:21.9% were MSI, 34.4% NSMP, 21.9% p53-abn and 0% POLEmut(p=0,537). Disease-free-survival (DFS) by molecular classification was similar between isolated lung recurrent patients after their treatment (figure 1).

Abstract 2022-RA-997-ESGO Figure 1
Abstract 2022-RA-997-ESGO Figure 1
View this table:
Abstract 2022-RA-997-ESGO Table 1

Conclusion Isolated lung recurrent patients locally-treated had the best DFS, OS, and a higher median-time-to-progression. Among tumors recurring in the lung, NSMP was the most frequent group. DFS was similar after lung recurrence treatment regarding molecular profile in the oligometastatic cohort.

https://doi.org/10.1136/ijgc-2022-ESGO.273

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.